Solodyn

Despite having hit its primary endpoint in the Phase 2b clinical trial of acne-treating BPX-01, Biopharmx Corp (NYSE: BPMX) plunged last week on a secondary endpoint miss on the Investigator’s Global Assessment (IGA) scale for acne severity. BioPharmX now looks to hit IGA goals as a coprimary...